Literature DB >> 25829418

Proteomics Differentiate Between Thyroid-Associated Orbitopathy and Dry Eye Syndrome.

Nina Matheis1, Franz H Grus2, Matthias Breitenfeld3, Ivo Knych3, Sebastian Funke4, Susanne Pitz5, Katharina A Ponto5, Norbert Pfeiffer5, George J Kahaly6.   

Abstract

PURPOSE: In patients with thyroid-associated orbitopathy (TAO), the dry eye syndrome occurs frequently, and symptoms and signs of both disorders overlap making early and accurate differential diagnosis difficult. A differentiation via specific markers is warranted.
METHODS: Tear fluid samples of 120 subjects with TAO, TAO + dry eye, dry eye, and controls were collected. The samples were measured using matrix-assisted laser desorption ionization mass spectrometry. The identified proteins were tested with antibody microarrays.
RESULTS: Proteomics identified deregulated proteins in TAO and dry eye. Compared with dry eye, proline-rich protein 1 (PROL1, P = 0.002); uridine diphosphate (UDP)-glucose-dehydrogenase (UGDH, P = 0.017); calgranulin A (S10A8, P < 0.0001); transcription-activator BRG1 (SMCA4, P < 0.0001); annexin A1 (P = 0.007); cystatin (P = 0.009); heat shock protein 27 (P = 0.03); and galectin (P = 0.04) were markedly downregulated in TAO. Compared with healthy controls, PROL1 (P < 0.05.); proline-rich protein 4 (PRP4, P < 0.05), S10A8 (P = 0.004) and SMCA4 (P = 0.002) were downregulated in TAO. In contrast, the proteins midasin and POTE-ankyrin-domain family-member I were upregulated in TAO versus healthy controls (P < 0.05). Protein dysregulation was associated with inflammatory response and cell death. Antibody microarray confirmed significant changes of PRP4, PROL1, and UGDH between TAO and dry eye or healthy controls (P < 0.01). The presence of these three proteins was negatively correlated with smoking (P < 0.05).
CONCLUSIONS: Proteomics of tear fluid demonstrated an upregulation of inflammatory proteins versus a downregulation of protective proteins in TAO, and a significantly different protein panel in TAO versus dry eye and/or controls. The spectrum of inflammatory and protective proteins might be a useful indicator for disease activity and ocular surface disease in patients with TAO.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25829418     DOI: 10.1167/iovs.15-16699

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  26 in total

Review 1.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

2.  Proteomics of Tear in Inactive Thyroid-Associated Ophthalmopathy.

Authors:  L Jiang; R Wei; J Diao; H Ding; W Wang; R Ao
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

Review 3.  The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves' ophthalmopathy.

Authors:  Hadi Khazaei; Danesh Khazaei; Rohan Verma; John Ng; Phillip A Wilmarth; Larry L David; James T Rosenbaum
Journal:  Exp Eye Res       Date:  2021-11-03       Impact factor: 3.467

4.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

5.  A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.

Authors:  Stephanie Hiu Ling Poon; Janice Jing-Chee Cheung; Kendrick Co Shih; Yau Kei Chan
Journal:  Rev Endocr Metab Disord       Date:  2022-01-23       Impact factor: 6.514

Review 6.  Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine.

Authors:  Suzanne Hagan; Eilidh Martin; Amalia Enríquez-de-Salamanca
Journal:  EPMA J       Date:  2016-07-13       Impact factor: 6.543

7.  A Quantitative Proteomics Approach to Clinical Research with Non-Traditional Samples.

Authors:  Rígel Licier; Eric Miranda; Horacio Serrano
Journal:  Proteomes       Date:  2016-10-17

8.  Tear proteome analysis in ocular surface diseases using label-free LC-MS/MS and multiplexed-microarray biomarker validation.

Authors:  Javier Soria; Arantxa Acera; Jesús Merayo-LLoves; Juan A Durán; Nerea González; Sandra Rodriguez; Nikitas Bistolas; Soeren Schumacher; Frank F Bier; Harald Peter; Walter Stöcklein; Tatiana Suárez
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

9.  Differentiation between thyroid-associated orbitopathy and Graves' disease by iTRAQ-based quantitative proteomic analysis.

Authors:  Jianshu Kang; Yunqin Li; Zhijian Zhao; Hong Zhang
Journal:  FEBS Open Bio       Date:  2021-05-26       Impact factor: 2.693

10.  Ocular Surface Changes in Patients with Thyroid Eye Disease: An Observational Clinical Study.

Authors:  Ibrahim Y Allam; Sihem Lazreg; Mohamed Shafik Shaheen; Mohamed Fahmy Doheim; Mai A Mohammed
Journal:  Clin Ophthalmol       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.